Radiotherapy in localized prostate cancer: a multicenter analysis evaluating tumor control and late toxicity after brachytherapy and external beam radiotherapy in 1293 patients.

Autor: Moll M; Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Matthias.moll@meduniwien.ac.at.; Department of Radiation Oncology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Matthias.moll@meduniwien.ac.at., Nechvile E; Department of Radiation Oncology, Klinik Hietzing, Vienna, Austria., Kirisits C; Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Komina O; Department of Radiation Oncology, Klinik Hietzing, Vienna, Austria., Pajer T; Department of Radiation Oncology, Klinik Hietzing, Vienna, Austria., Kohl B; Department of Radiation Oncology, Klinik Hietzing, Vienna, Austria., Miszczyk M; Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.; IIIrd, Maria Skłodowska-Curie National Research Institute of Oncology, Wybrzeże Armii Krajowej 15, 44-102, Gliwice, Poland., Widder J; Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Knocke-Abulesz TH; Department of Radiation Oncology, Klinik Hietzing, Vienna, Austria., Goldner G; Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Jazyk: angličtina
Zdroj: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 2024 Aug; Vol. 200 (8), pp. 698-705. Date of Electronic Publication: 2024 Mar 15.
DOI: 10.1007/s00066-024-02222-w
Abstrakt: Background and Purpose: Comparing oncological outcomes and toxicity after primary treatment of localized prostate cancer using HDR- or LDR-mono-brachytherapy (BT), or conventionally (CF) or moderately hypofractionated (HF) external beam radiotherapy.
Materials and Methods: Retrospectively, patients with low- (LR) or favorable intermediate-risk (IR) prostate cancer treated between 03/2000 and 09/2022 in two centers were included. Treatment was performed using either CF with total doses between 74 and 78 Gy, HF with 2.4-2.6 Gy per fraction in 30 fractions, or LDR- or HDR-BT. Biochemical control (BC) according to the Phoenix criteria, and late gastrointestinal (GI), and genitourinary (GU) toxicity according to RTOG/EORTC criteria were assessed.
Results: We identified 1293 patients, 697 with LR and 596 with IR prostate cancer. Of these, 470, 182, 480, and 161 were treated with CF, HF, LDR-BT, and HDR-BT, respectively. For BC, we did not find a significant difference between treatments in LR and IR (p = 0.31 and 0.72). The 5‑year BC for LR was between 93 and 95% for all treatment types. For IR, BC was between 88% in the CF and 94% in the HF group. For CF and HF, maximum GI and GU toxicity grade ≥ 2 was between 22 and 27%. For LDR-BT, we observed 67% grade ≥ 2 GU toxicity. Maximum GI grade ≥ 2 toxicity was 9%. For HDR-BT, we observed 1% GI grade ≥ 2 toxicity and 19% GU grade ≥ 2 toxicity.
Conclusion: All types of therapy were effective and well received. HDR-BT caused the least late toxicities, especially GI.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: